Quick answer

Tirzepatide for weight (Nov 2023) and obstructive sleep apnea (Dec 2024) — the SURMOUNT drug with the class’s best approved numbers and the LillyDirect vial channel that reset cash pricing. The OSA label is also a coverage door the weight label can’t open.

MoleculeTirzepatideLabelChronic weight management (2023) · Moderate-to-severe OSA with obesity (2024)Dose ladder2.5 → 15 mg weekly · single-dose autoinjectors; vials via LillyDirectKey trialsSURMOUNT-1: to −20.9% · SURMOUNT-OSA: AHI −25–29 events/hr · SURMOUNT-4: withdrawal/regainCash laneLillyDirect vials — doses and prices have expanded; verify currentCoverage noteThe OSA indication reaches plans — Medicare included — that weight alone cannot

Deeper data: the trial index holds every figure above with sources; the OSA file, working the indications.

Zepbound is tirzepatide labeled for chronic weight management — and, since December 2024, the first medication ever approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Indications

Adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, alongside diet and activity; and moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA trials’ large reductions in apnea events (explainer). Same molecule as Mounjaro; different label.

Dosing

Start 2.5 mg weekly for four weeks — explicitly a tolerability step — then 5 mg, with optional escalations in 2.5 mg increments to a 15 mg maximum, spaced at least four weeks. Maintenance in the pivotal trials clustered at 10–15 mg; price the dose you’ll actually stay on, not the one you start on.

Formats and buying channels

Single-dose pens through pharmacy channels, and single-dose vials sold through Lilly’s direct self-pay channel (LillyDirect) at cash prices far below list — vial tiering and eligibility have changed more than once, so verify the current numbers on Lilly’s own pages before deciding. With commercial insurance covering it, the savings card can cut copays substantially. Telehealth platforms increasingly route cash buyers into these manufacturer channels; our provider files track who does this cleanly.

Safety essentials

Everything on the tirzepatide molecule page applies verbatim: boxed thyroid warning, GI-dominant side effects during titration, the oral-contraceptive interaction, gallbladder and pancreatitis cautions, surgical disclosure.

Common confusions

Zepbound vs Mounjaro is a label difference, not a drug difference — which matters for insurance coding, not biology. “Zepbound tablets” do not exist; no oral tirzepatide is approved (analysis). And compounded “tirzepatide” is not Zepbound — different legal lane, different quality controls, mapped here.

Costs in practice

List price sits near four figures a month — around the $1,000–1,100 mark historically, verify current — but almost nobody rational pays it. The realistic tiers: a covered prescription with the savings card (commercial insurance) can land near the bottom of the market; LillyDirect single-dose vials give cash buyers approved product at a fraction of list, with tiering by dose that has shifted more than once; and compounded tirzepatide flat rates sit below that with legal-lane caveats attached. Run any quote through the calculator at your likely maintenance dose — 10 or 12.5 mg is a more honest planning assumption than 2.5.

Who it fits, who should look elsewhere

Zepbound is the efficacy ceiling among approved options and the obvious first conversation for most cash-capable or well-insured patients — and for anyone whose sleep apnea qualifies under the OSA indication, since that label can unlock coverage “weight loss” never will. Look elsewhere if injections are a hard no (Rybelsus or the oral pipeline), if budget forces the generic route (liraglutide), or if your insurer covers only semaglutide — a formulary reality our coverage file explains.

References

Zepbound prescribing information — pi.lilly.com. SURMOUNT-1; SURMOUNT-OSA, NEJM 2024. Cost worksheets: calculator.